Cytarabine Liposome Injection Articles

Italy’s Sigma-Tau to takeover Enzon business for some $327 million in cash plus royalties

10 November 2009

Enzon Pharma explores options, including the sale of its specialty drugs unit

18 August 2008

SkyePharma Inc changes name to Pacira

2 July 2007

A turnaround for SkyePharma with injectables unit sale for $82M

15 January 2007

SkyePharma's 1st-half 2006 loss doubles

9 October 2006

Enzon swings to $286M loss in 4th-qtr 2005

13 March 2006

SkyePharma reviews options as no buyer found

13 February 2006

SkyePharma's full-year 2003 sales down 24%

10 May 2004

Revenues warnings from SkyePharma

5 January 2004

NPS Pharma and Enzon to merge in $1.6B deal; aim to be "a new biotech leader"

3 March 2003

Return to form for life sciences in 2003 after "dismal" 2002, say analysts

17 February 2003

SkyePharma licenses key drugs to Endo

13 January 2003

SkyePharma buys back Depocyt rights

6 January 2003

SkyePharma confident about reaching profitability target in 2nd-half 2001

20 September 2001

SkyePharma's DepoCyte granted EU approval

9 August 2001

SkyePharma licenses DepoCyte to Elan in Europe

26 July 2001

Nippon-Shinyaku in pact with SkyePharma

3 July 2001

Stock Commentary - Europe

5 April 2001

SkyePharma posts strong set of full-year results; profitable by end of 2001

2 April 2001

Stock Commentary - Europe

15 March 2001

SkyePharma's DepoCyt gains US clearance

5 March 2001

SkyePharma passes credibility test, with profitability aim soon to be

18 January 2001

SkyePharma looks to move into the black within next 12 months, Solarase

29 September 2000

Paladin licenses Canadian rights to DepoCyt

10 July 2000

SkyePharma turnover up 62.4% in 1999

18 May 2000

SkyePharma outlines mission to become major player in drug delivery

23 February 2000

Busy year for NCEs as major new compound classes launched

6 January 2000

SkyePharma looking to move into the black

3 September 1999

US launch for DepoCyt

25 May 1999

SkyePharma sales down, losses continue

20 April 1999

DepoCyt cleared in USA for NHL complication

6 April 1999

DepoCyt Recommended For Approval In USA

19 November 1998

Savedar Application Withdrawn In EU

22 October 1998

SkyePharma Expands In USA; Offers $56 Million For DepoTech

20 October 1998

DepoTech Submits NDA For DepoCyt Again

13 October 1998

FDA Says Depotech's DepoCyt "Non-Approvable"

27 May 1998

DepoTech To File More Data On DepoCyt

9 March 1998

DepoTech Files MAA For Savedar

22 January 1998

DepoCyt Fails To Get US Panel Support

12 January 1998

DepoTech's NDA For DepoCyt Accepted For Final Review; Deal With P&U

10 July 1997

DepoTech Starts Filing NDA For DepoCyt

2 December 1996

DepoCyt Heading For Commercialization

28 October 1996

US Generic, Drug Delivery Firms Discuss Strategies

3 June 1996

Showing 1-43 of 43 articles

Go to beginningPrevious
  • 1
NextGo to end